NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to...
- Phase 2a Enrollment Completed in 45 mg Safety Cohort: Median Overall Survival (OS) Not Reached; 89% of Patients Alive...
- Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently...
European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced...
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
The anticipated acquisition aligns to GE HealthCare’s precision care strategy with the goal of strengthening the company’s digital solutions across...
SAN ANTONIO--(BUSINESS WIRE)--#BIAF--Here is a summary of the latest news about bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company...
Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to...
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s...
COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust...
Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more...
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety...
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer...
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024...
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader...
iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase...